Data from the Phase II ARIEL2 study to prospectively identify patients with ovarian cancer likely to respond to rucaparib was presented last week by Elizabeth Swisher, M.D., professor of obstetrics and gynecology and adjunct professor of medical genetics at the University of Washington School of Medicine, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics [link to conference site] in Barcelona, Spain. This study evaluates a novel companion diagnostic approach that identifies patients with a “BRCAness” molecular signature in addition to genomic alterations in the BRCA1 and BRCA2 genes. In patients with the BRCAness signature, 40% had an overall response to rucaparib, compared to 8% in patients who tested negative for the targets in this study. This diagnostic may expand the size of the patient population to benefit from rucaparib therapy and is enabled by Foundation Medicine’s comprehensive platform that detects all classes of genomic alterations in cancer related genes. The data results from Foundation Medicine’s partnership with Clovis Oncology, the developer of rucaparib. Additional details about the study can be found in the press release issued to announce the data.